Study on the minimum effective concentration of simethicone and impact factors of gastric mucus and bubbles volume

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043397

Enrollment

Unknown

Registered

2021-02-13

Start date

2021-02-25

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric and duodenal diseases, not specified

Interventions

positive control group:100mg/100ml simethicone

experimental group:20mg/100ml simethicone

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients aged between 18 and 80 years undergo routine esophagogastroduodenoscopy examination.

Exclusion criteria

Exclusion criteria: 1. Acute upper gastrointestinal bleeding; 2. Serious heart, lung, liver and kidney diseases; 3. Upper gastrointestinal surgery history; 4. Pregnant or lactating women; 5. Psychosis; 6. Allergic to simethicone; 7. Refuse to sign informed consent.

Design outcomes

Primary

Measure	Time frame
visibility score;subtle lesion;	—

Secondary

Measure	Time frame
examination time;flush times;	—

Countries

China

Contacts

Public ContactRui Ji

Qilu Hospital of Shandong University

qljirui@163.com+86 18560086103

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026